The Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation has launched a new voluntary bundled payment model called Bundled Payments for Care Improvement Advanced.
Abilify MyCite (aripiprazole tablets with sensor; Otsuka Pharmaceutical), the first digital ingestion tracking system, has been approved by the U.S. Food and Drug Administration.
CSL Behring noted the potential for fading print with more effect on the expiration dating on the patient tear-off portion of the vial label.
Researchers have found antibiotics can be counterproductive and weaken the immune system’s ability to fight off bacteria.
A nationwide epidemiological study showed cancer patients who continuously used disulfiram (Antabuse), a drug prescribed to alcoholics to prevent them from drinking, have a lower risk of death from cancer compared to those who stopped using the drug once diagnosed.
The Centers for Medicare and Medicaid Services has proposed a 1.84 percent increase in 2019 Medicare payments to health insurers that manage Medicare Advantage insurance plans for more than 20 million elderly and disabled people.
A Phase III study involving 109 male participants with hemophilia A and inhibitors showed that once-weekly subcutaneous prophylactic administration of an investigational bispecific humanized monoclonal antibody (emicizumab; ACE910) was associated with a significantly lower rate of bleeding events than no prophylaxis.
The U.S. Department of Health and Human Services has proposed 2018 updates to the Medicare hospital outpatient prospective payment system to decrease Medicare Part B payments to hospitals for 340B drugs by almost 30 percent.
The U.S. Senate passed the Creating High-Quality Results and Outcomes Necessary to Improve Chronic(CHRONIC) Care Act of 2017, which aims to improve care for seniors with chronic conditions.
The U.S. Food and Drug Administration has approved Agios Pharmaceuticals’ Idhifa (enasidenib) to treat acute myelogenous leukemia.
The U.S. Food and Drug Administration has approved CSL Behring’s Haegarda (C1 esterase inhibitor subcutaneous [human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients.
The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
